Triple

T7168806
Position Surface form Disambiguated ID Type / Status
Subject Prescription Drug User Fee Act of 1992 E167139 entity
Predicate relatedTo P37 FINISHED
Object Biologics Price Competition and Innovation Act E642124 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Biologics Price Competition and Innovation Act | Statement: [Prescription Drug User Fee Act of 1992, relatedTo, Biologics Price Competition and Innovation Act]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Biologics Price Competition and Innovation Act
Context triple: [Prescription Drug User Fee Act of 1992, relatedTo, Biologics Price Competition and Innovation Act]
  • A. Biologics Price Competition and Innovation Act chosen
    The Biologics Price Competition and Innovation Act is a U.S. law that created an abbreviated regulatory pathway for approval of biosimilar and interchangeable biological products to promote competition while balancing incentives for innovation.
  • B. Food and Drug Administration Amendments Act of 2007
    The Food and Drug Administration Amendments Act of 2007 is a U.S. law that expanded the FDA’s authority over drug and device safety, clinical trials, and post-market surveillance, while enhancing transparency and user fee programs.
  • C. Drug Price Competition and Patent Term Restoration Act of 1984
    The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, is a U.S. law that streamlined the approval of generic drugs while providing patent term extensions to brand-name drug manufacturers to balance innovation and competition.
  • D. Food and Drug Administration Safety and Innovation Act of 2012
    The Food and Drug Administration Safety and Innovation Act of 2012 is a U.S. federal law that reauthorized and expanded FDA user fee programs while enhancing the agency’s authority over drug and medical device safety, innovation, and supply chain oversight.
  • E. 21st Century Cures Act
    The 21st Century Cures Act is a U.S. federal law enacted in 2016 that accelerates medical product development and innovation, expands funding for biomedical research and mental health services, and modernizes the regulation of drugs and medical devices.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69c68888c10c819095e0383020225758 completed March 27, 2026, 1:39 p.m.
NER Named-entity recognition batch_69c6e85c606081909f76d76fc5b90bc8 completed March 27, 2026, 8:28 p.m.
NED1 Entity disambiguation (via context triple) batch_69c7b9094a8c81909e9d5b91ec714831 completed March 28, 2026, 11:18 a.m.
Created at: March 27, 2026, 2:48 p.m.